Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation

Witte, T. de; Hoogenhout, J.; Pauw, Ben de; Holdrinet, R. S. G.; Janssen, J; Wessels, J.; Daal, W van; Hustinx, T. W. J.; Haanen, C.

doi:10.1182/blood.v67.5.1302.1302

Cited by 95 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13/36 non‐identical sibling combinations tested represented actual recipient–donor pairs. In these cases donor marrow was partially depleted of lymphocytes by counterflow centrifugation in order to obtain a graft containing 0.7 × 10 6 T lymphocytes per kg body weight (de Witte et al , 1986). The standard conditioning regimen consisted of cyclophosphamide (2 × 60 mg/kg body weight) and total body irradiation (2 × 4.5 Gy).…”

Section: Methodsmentioning

confidence: 99%

Interferon‐γ‐based mixed lymphocyte culture as a selection tool for allogeneic bone marrow donors other than identical siblings

Meer¹,

Wissink

Schattenberg

et al. 1999

Br J Haematol

View full text Add to dashboard Cite

Selection procedures in bone marrow transplantation (BMT) would benefit from the development of easy-to-perform cellular assays with high discriminative power. We tested a cytokine-based mixed lymphocyte culture (MLC) and compared its outcome to the routinely used MLC, helper T-lymphocyte precursor (HTLp)-f and cytotoxic T-lymphocyte precursor (CTLp)-f assays. Interferon (IFN)gamma was selected as a marker cytokine for (deleterious) T-helper 1 like responses and 36 (potential) BMT donor-recipient pairs were analysed. The IFNgamma-MLC appeared sensitive to HLA class II (subtype) differences, but not to isolated class I differences, or to mismatches other than HLA (identical siblings). The test enabled a distinction between combinations with positive MLC (proliferation) and HTLp-f, exemplified by the fact that although high IFNgamma levels were observed in the class II mismatched group, certain DRB3, DQB1-subtype and DRB1-subtype mismatches did not give rise to IFNgamma production. This might be of relevance for the detection of so-called permissible mismatches. With regard to prediction of acute graft-versus-host disease (aGVHD) in unrelated BMT, the data indicated that high levels of IFNgamma coincided with severe aGVHD, whereas low levels were largely associated with grades 0-I. However, in the case of isolated class I mismatches the test had no predictive value. The cell-saving IFNgamma-MLC provides an alternative for the assays currently in use, but should be employed along with an assay that is sensitive to class I differences to correct for false negatives. Consequently, a combination of IFNgamma-MLC and CTLp-f assays seems most promising for donor selection, other than identical siblings.

show abstract

Section: Methodsmentioning

confidence: 99%

Interferon‐γ‐based mixed lymphocyte culture as a selection tool for allogeneic bone marrow donors other than identical siblings

Meer¹,

Wissink

Schattenberg

et al. 1999

Br J Haematol

View full text Add to dashboard Cite

show abstract

Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia

Witte

Muus

Pauw

et al. 1990

Cancer

102

View full text Add to dashboard Cite

Intensive antileukemic treatment was evaluated in 22 patients with secondary acute myelogenous leukemia (sAML) and 14 patients with myelodysplastic syndrome (MDS). Results of combination remission-induction chemotherapy were compared with 126 patients contemporarily treated for primary AML. The duration of hypoplasia, induced by remission induction chemotherapy, tended to be longer in the sAML and MDS patients when compared to de novo AML, but reached significance only for the duration of thrombocytopenia: 26 days versus 18 days (P less than 0.01). The number of hypoplastic deaths during remission-induction chemotherapy of patients with sAML and MDS was low. Four of the 36 patients treated for sAML or MDS died during hypoplastic phases induced by remission-induction chemotherapy. The complete remission (CR) rates were similar in primary AML (67%), sAML (62%), and MDS (64%). The CR rates of patients younger than 45 years were 75% for de novo AML, 75% for sAML, and 71% for MDS. Remission rates in patients older than 45 years were identical in the three subgroups but significantly (P less than 0.005) inferior to those obtained in younger patients: 56%, 50%, and 57%, in de novo AML, sAML, and MDS, respectively. The remission duration without bone marrow transplant (BMT) was significantly shorter (P less than 0.01) in MDS and sAML when compared with primary AML. Long-lasting CR in MDS and sAML was only obtained in three of the six patients treated with allogeneic BMT. Intensive antileukemic therapy could be considered in young patients with MDS and life-threatening cytopenias or patients with sAML.

show abstract

Recurrent adult nephroblastoma long-term remission after surgery plus adjuvant high-dose chemotherapy, radiation therapy, and allogeneic bone marrow transplantation

Hupperets¹,

Havenith

Blijham³

1992

Cancer

View full text Add to dashboard Cite

Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation

Cited by 95 publications

References 35 publications

Interferon‐γ‐based mixed lymphocyte culture as a selection tool for allogeneic bone marrow donors other than identical siblings

Interferon‐γ‐based mixed lymphocyte culture as a selection tool for allogeneic bone marrow donors other than identical siblings

Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia

Recurrent adult nephroblastoma long-term remission after surgery plus adjuvant high-dose chemotherapy, radiation therapy, and allogeneic bone marrow transplantation

Contact Info

Product

Resources

About